At first glance, the studies performed by Hamanishi and Webb seem to be contradictory, and the major differences in PDL-1 expression reported by the authors seem to be related to the clones used in the immunohistochemical studies, as suggested by Webb et al. For this reason, the evaluation of PDL-1 expression in tumor cells from ovarian carcinomas (regardless of type), as well as from immune cells associated with tumors, seems to require an appropriate protocol and reporting system, similar to that used for lung carcinomas, for better traceability of results. The gene discussed is CD274; the disease is ovarian carcinoma.